Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study

Background Assessing the safety of SARS-CoV-2 mRNA vaccines and the effect of immunotherapies on the seroconversion rate in patients with autoimmune neurological conditions (ANC) is relevant to clinical practice. Our aim was to assess the antibody response to and safety of SARS-CoV-2 mRNA vaccines i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neurology 2022-08, Vol.269 (8), p.4000-4012
Hauptverfasser:	Giannoccaro, Maria Pia, Vacchiano, Veria, Leone, Marta, Camilli, Federico, Zenesini, Corrado, Panzera, Ivan, Balboni, Alice, Tappatà, Maria, Borghi, Annamaria, Salvi, Fabrizio, Lugaresi, Alessandra, Rinaldi, Rita, Di Felice, Giulia, Lodi, Vittorio, Lazzarotto, Tiziana, Liguori, Rocco
Format:	Artikel
Sprache:	eng
Schlagworte:	2019-nCoV Vaccine mRNA-1273 Adult Aged Antibodies Antibodies, Viral Antibody response Autoimmune Diseases of the Nervous System BNT162 Vaccine CD20 antigen COVID-19 - prevention & control COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Fingolimod Hydrochloride Health care Humans Immune response (humoral) Immunity, Humoral Immunoglobulin G Immunotherapy Longitudinal Studies Medical personnel Medicine Medicine & Public Health Middle Aged Monoclonal antibodies mRNA mRNA vaccines Neurological diseases Neurology Neuroradiology Neurosciences Original Communication Patients Safety SARS-CoV-2 Seroconversion Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!